Zobrazeno 1 - 10
of 614
pro vyhledávání: '"David, Planchard"'
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, BRAF sequencing approaches, and unmet needs. The BRAFV60
Externí odkaz:
https://doaj.org/article/5d4d7a8e57754e16812b1b989f4ffe66
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/b01d9d85a526473fad40622c3a74faba
Autor:
Myriam Mirza, Aseem Shrivastava, Cecile Matthews, Natasha Leighl, Calvin S. H. Ng, David Planchard, Sanjay Popat, Julia Rotow, Egbert F. Smit, Ross Soo, Masahiro Tsuboi, Fan Yang, Brendon Stiles, Christian Grohe, Yi-Long Wu
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
IntroductionOsimertinib is recommended by major guidelines for use in the adjuvant setting in patients with EGFR mutation-positive NSCLC following the significant improvement in disease-free survival observed in the Phase III ADAURA trials. Due to li
Externí odkaz:
https://doaj.org/article/16b99c860cb44565b5aca42740985756
Autor:
Caroline Robert, Aurélien Marabelle, Fabrice Barlesi, Samy Ammari, David Planchard, Siham Farhane, Paul-Henry Cournède, Pierre Decazes, Younes Belkouchi, Léo Mottay, Littisha Lawrance, Antoine de Prévia, Hugues Talbot, Florian Guisier, Tony Ibrahim, Pierre Vera, Nathalie Lassau
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Our aim was to explore the prognostic value of anthropometric parameters in a large population of patients treated with immunotherapy.Methods We retrospectively included 623 patients with advanced non-small cell lung cancer (NSCLC) (n=318)
Externí odkaz:
https://doaj.org/article/45c25158807d48c79b5b5abe405896a3
Autor:
Antonin Levy, Jonathan Khalifa, Etienne Martin, Angela Botticella, Clément Quevrin, Pernelle Lavaud, Mihaela Aldea, Benjamin Besse, David Planchard, Fabrice Barlesi, Eric Deutsch, Carole Massabeau, Jérôme Doyen, Cécile Le Péchoux
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 41, Iss , Pp 100637- (2023)
Introduction: The role of local ablative treatments, including stereotactic body radiotherapy (SBRT), is an area of active research in oligometastatic patients. Small cell lung cancer (SCLC) has a poor prognosis, with common diffuse metastatic evolut
Externí odkaz:
https://doaj.org/article/c92fcb16210c45e78b303dcdc65081ef
Autor:
Giannis Mountzios, MD, PhD, David Planchard, MD, PhD, Giulio Metro, MD, PhD, Dora Tsiouda, Arsela Prelaj, MD, Sofia Lampaki, MD, PhD, Walid Shalata, MD, Mariona Riudavets, Petros Christopoulos, MD, PhD, Nicolas Girard, MD, PhD, Víctor Albarrán-Artahona, Rosario Garcia Campelo, MD, PhD, Konstantinos Samitas, MD, PhD, Giuseppe Luigi Banna, MD, Ioannis Boukovinas, MD, PhD, Abed Agbarya, MD, PhD, Anna Koumarianou, MD, Eleni-Isidora Perdikouri, Paris Kosmidis, Helena Linardou, MD, PhD, David Mauri, MD, PhD, Dimitrios Mavroudis, MD, PhD, Ilias Athanasiadis, MD, PhD, Haralambos Kalofonos, Nikolaos Xenidis, MD, PhD, Ippokratis Korantzis, MD, Alexandros Ardavanis, Grigorios Rallis, MD, Achille Bottiglieri, Konstantinos Efthymiadis, MD, Georgios Oikonomopoulos, MD, Alexandros Kokkalis, MD, Emmanouil Saloustros, MD, PhD, Nikolaos Tsoukalas, MD, Dimitra Bartzi, MD, Panagiota Economopoulou, Amanda Psyrri, MD, PhD, Martin Reck, Giuseppe Lo Russo, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 1, Pp 100433- (2023)
Introduction: Real-world evidence regarding molecular epidemiology and management patterns of patients with EGFR exon-20 mutated, advanced NSCLC outside the context of clinical trials is lacking. Methods: We created a European registry for patients w
Externí odkaz:
https://doaj.org/article/1da16fe8f3c8428eb04732eb21d2f835
Autor:
Diana Schaufler, David F. Ast, Hannah L. Tumbrink, Nima Abedpour, Lukas Maas, Ayla E. Schwäbe, Inga Spille, Stefanie Lennartz, Jana Fassunke, Mihaela Aldea, Benjamin Besse, David Planchard, Lucia Nogova, Sebastian Michels, Carsten Kobe, Thorsten Persigehl, Theresa Westphal, Sophia Koleczko, Rieke Fischer, Jan-Phillip Weber, Janine Altmüller, Roman K. Thomas, Sabine Merkelbach-Bruse, Oliver Gautschi, Laura Mezquita, Reinhard Büttner, Jürgen Wolf, Martin Peifer, Johannes Brägelmann, Matthias Scheffler, Martin L. Sos
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
Abstract Activation of MAPK signaling via BRAF mutations may limit the activity of EGFR inhibitors in EGFR-mutant lung cancer patients. However, the impact of BRAF mutations on the selection and fitness of emerging resistant clones during anti-EGFR t
Externí odkaz:
https://doaj.org/article/2fe94ce5763c49248add719a2c82fe60
Autor:
Mariona Riudavets, MD, PhD, Arshid Azarine, MD, MSc, Sondes Smaali, MD, Young-Wouk Kim, MD, Vincent Thomas de Montpréville, MD, Alina Miruna Grecea, MD, Charles Naltet, MD, Annas Gazzah, MD, David Planchard, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 12, Pp 100432- (2022)
Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the mos
Externí odkaz:
https://doaj.org/article/f9a04cb6b8234e7793c0570ef7f55d89
Autor:
Mihaela Aldea, Rakiba Belkhir, Emeline Colomba, Pierre Blanchard, Francois-Xavier Danlos, Angela Botticella, Mario Terlizzi, Eric Deutsch, Cecile Le Péchoux, David Planchard, Jean-Marie Michot, Benjamin Besse, Antonin Levy
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Radiotherapy can trigger immune-related out-of-field “abscopal” response. We report a patient with advanced NSCLC (non-small cell lung cancer) receiving long-term anti-PD1 (programmed cell death protein 1) who have developed out-of-field immune-r
Externí odkaz:
https://doaj.org/article/afbec721841a43c4909ec3c0a41a8b90
Autor:
Ines Malenica, Julien Adam, Stéphanie Corgnac, Laura Mezquita, Edouard Auclin, Isabelle Damei, Laetitia Grynszpan, Gwendoline Gros, Vincent de Montpréville, David Planchard, Nathalie Théret, Benjamin Besse, Fathia Mami-Chouaib
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Response to PD-1 checkpoint blockade is unpredictable in lung cancer patients. Here authors show in human lung and mouse tumour models that low or absent αV integrin expression leads to better tumour growth control by anti-PD-1 via reduced TGF-β ac
Externí odkaz:
https://doaj.org/article/9f76efab27fb4f01b8031919754f4805